Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H25N4O8.Gd |
Molecular Weight | 558.64 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1
InChI
InChIKey=GFSTXYOTEVLASN-UHFFFAOYSA-K
InChI=1S/C16H28N4O8.Gd/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H25N4O8 |
Molecular Weight | 401.3917 |
Charge | -3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7960618http://www.prnewswire.com/news-releases/fda-approves-dotarem-gadoterate-meglumine-first-macrocyclic-and-ionic-gadolinium-based-contrast-agent-in-usa-199354771.html
Curator's Comment: # Schering AG (now subsidiary of Bayer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/31179770 |
105.0 mM [Ki] | ||
Target ID: P52209 Gene ID: 5226.0 Gene Symbol: PGD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20235752 |
73.0 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DOTAREM Approved UseIndicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Launch Date1.36373758E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
PubMed
Title | Date | PubMed |
---|---|---|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. | 2005 Apr 20 |
|
Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C. | 2006 Apr 28 |
|
Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. | 2006 Feb |
|
Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data. | 2007 Aug |
|
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. | 2008 Apr |
|
Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. | 2008 Aug |
|
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells. | 2008 Jul |
|
Renal failure and gadolinium. The number of documented cases is rising. | 2008 Oct |
|
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency. | 2009 Dec |
|
Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch. | 2009 Dec |
|
Large sample of nephrogenic systemic fibrosis cases from a single institution. | 2009 Oct |
|
Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity. | 2010 Aug |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:02:35 UTC 2023
by
admin
on
Fri Dec 15 16:02:35 UTC 2023
|
Record UNII |
QVF9Y6955W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
V08CA02
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
||
|
WHO-VATC |
QV08CA02
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6253
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
DTXSID801027873
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
158536
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
m11732
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
C174900
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
73732
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
Gadoterate
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
SUB07865MIG
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
QVF9Y6955W
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
72573-82-1
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
131330-52-4
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
ALTERNATIVE | |||
|
GADOTERIC ACID
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
DB09132
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
100000089855
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY | |||
|
4559
Created by
admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |